Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

243.60 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Resmed Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
10 Biggest Price Target Changes For Monday
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday. 
Via Benzinga
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May. 
Via Benzinga
If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today
ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of... 
Via Benzinga
ResMed Earnings Perspective: Return On Invested Capital
Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters. 
Via Benzinga
What 3 Analyst Ratings Have To Say About ResMed
Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract
Via Benzinga
What 5 Analyst Ratings Have To Say About ResMed
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings For ResMed
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Earnings Outlook For ResMed
ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Recap: ResMed Q2 Earnings
ResMed (NYSE:RMD) reported its Q2 earnings results on Thursday, January 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ResMed missed... 
Via Benzinga
Earnings Scheduled For January 27, 2022
Companies Reporting Before The Bell • SAP (NYSE:SAP) is estimated to report quarterly earnings at $1.87 per share on revenue of $9.10 billion. •... 
Via Benzinga
Sleep Apnea Device Maker Resmed Sees Improved Relative Strength
Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
Ten Healthcare Companies With High Payout Ratio
The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low. 
Via Talk Markets
3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives
Energy and commodity plays were top performers Wednesday. 
Via Investor's Business Daily
Markets Fall Amid Rising Oil Prices
U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also... 
Via Benzinga
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. 
Via InvestorPlace
Ominous Death Cross Forms On ResMed's Chart
If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
ResMed's Return on Invested Capital Overview
According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01%... 
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall
ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations... 
Via Benzinga
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview: ResMed
ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the... 
Via Benzinga
This Company Just Made a Possibly Lucrative Acquisition — What's Next?
Photo by Ccfb on Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The global... 
Via Benzinga
What 4 Analyst Ratings Have To Say About ResMed
Within the last quarter, ResMed (NYSE:RMD) has observed the following analyst ... 
Via Benzinga
Take Action To Unlock Supply Chain Disruption Issues
Businesses are grappling with supply chain disruption. And beating this challenge requires leaders to take decisive action right now. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022
Upgrades According to Morgan Stanley, the prior rating for SunPower Corp (NASDAQ: 
Via Benzinga
4 Low-Beta Stocks To Buy For A Volatile Market
Global economic uncertainty, inflationary pressure, a disappointing jobs report, and concerns around the COVID-19 Omicron variant are fostering market volatility. So, against this backdrop, we think it... 
Via Talk Markets
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX: 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.